** Drugmaker Halozyme HALO.O sues Merck MRK.N over a subcutaneous version of cancer drug Keytruda, which HALO says uses a drug delivery technology patented by it
** Shares of HALO rise 1% to $59.03
** Last month, MRK, who is banking on the new version of Keytruda to protect it against a patent expiry in 2028, said that it plans to launch the drug on October 1
** The ultimate outcome of Halozyme's lawsuit should have no impact on the company's current or future licenses, revenues, or programs related to a newer drug delivery technology — TD Cowen
** "We see significant upside opportunity for Halozyme if they are awarded a royalty on Keytruda SC sales" — brokerage
** Including session's move, HALO stock up 23.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。